Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - BioMed Realty Trust Inc | d937311dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 29, 2015
BioMed Realty Trust, Inc.
BioMed Realty, L.P.
(Exact name of registrant as specified in its charter)
| Maryland | 1-32261 (BioMed Realty Trust, Inc.) 000-54089 (BioMed Realty, L.P.) |
20-1142292 (BioMed Realty Trust, Inc.) 20-1320636 (BioMed Realty, L.P.) | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File No.) |
(I.R.S. Employer Identification No.) |
17190 Bernardo Center Drive
San Diego, California 92128
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: (858) 485-9840
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 2.06 | Material Impairments. |
On May 29, 2015, BioMed Realty Trust, Inc., through its operating partnership subsidiary, BioMed Realty, L.P. (collectively, the “Company”), sold its property located at 145 King of Prussia Road in Radnor, Pennsylvania (the “KOP Property”). As a result, the Company expects to record a non-cash impairment charge of approximately $32 million in the second quarter of 2015. The non-cash impairment charge represents the excess of the book value of the KOP Property over the net proceeds from the sale.
| Item 7.01 | Regulation FD Disclosure. |
The information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Item 7.01.
On May 29, 2015, the Company issued a press release regarding the sale of the KOP Property. The text of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | The following exhibits are furnished herewith: |
| Exhibit |
Description of Exhibit | |
| 99.1 | Press release issued by BioMed Realty Trust, Inc. on May 29, 2015. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrants have duly caused this report to be signed on their behalf by the undersigned hereunto duly authorized.
| Date: May 29, 2015 |
BIOMED REALTY TRUST, INC. | |||||||
| By: | /s/ GREG N. LUBUSHKIN | |||||||
| Name: | Greg N. Lubushkin | |||||||
| Title: | Chief Financial Officer | |||||||
| BIOMED REALTY, L.P. | ||||||||
| By: BioMed Realty Trust, Inc. | ||||||||
| its General Partner | ||||||||
| By: | /s/ GREG N. LUBUSHKIN | |||||||
| Name: | Greg N. Lubushkin | |||||||
| Title: | Chief Financial Officer | |||||||